Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

NCT00838526 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

DRUG: Rabeprazole ER
DRUG: Ranitidine

Sponsor

Eisai Inc.